Literature DB >> 7694438

Extracranial blood flow, pain and tenderness in migraine. Clinical and experimental studies.

K Jensen1.   

Abstract

Migraine pain has traditionally been ascribed to dilatation of primarily extracranial arteries. Such dilatation has, however, not been demonstrated so far. Studies of microcirculation reveal no major hyperperfusion or ischemia in the temporal muscle or the subcutaneous tissue in the temporal region during attacks of migraine. However, a reduction in the orthostatic reactivity of the subcutaneous arterioles was observed on the side of the headache. Increased tenderness of the pericranial myofascial tissues is observed during migraine attacks, particularly on the side of the headache. Increased tension of pericranial muscles on the other hand is not a constant finding and migraine attacks are not induced by experimentally increased tension of the temporal and masseter muscles. Extracranial pain and tenderness may, however, be induced experimentally by intramuscular injections of hypertonic saline and potassium chloride as well as of endogenous substances like bradykinin with 5-hydroxytryptamine and bradykinin with substance P. The extracranial arteries and myofascial structures are both supplied by unmyelinated trigeminal sensory nerve fibers containing a variety of neuropeptides which are released during migraine attacks. Axonal reflexes between extracranial arteries and neighbouring myofascial tissues as well as referred pain mechanisms may account for the observed tenderness during migraine attacks.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694438

Source DB:  PubMed          Journal:  Acta Neurol Scand Suppl        ISSN: 0065-1427


  10 in total

1.  Painful scalp arteries in migraine.

Authors:  Carlo Cianchetti; Maria Giuseppina Ledda; Maria Celeste Serci; Francesco Madeddu
Journal:  J Neurol       Date:  2010-05-09       Impact factor: 4.849

Review 2.  The science of migraine.

Authors:  Rami Burstein; Moshe Jakubowski; Steven D Rauch
Journal:  J Vestib Res       Date:  2011       Impact factor: 2.435

3.  Improved identification of allodynic migraine patients using a questionnaire.

Authors:  A Ashkenazi; S Silberstein; M Jakubowski; R Burstein
Journal:  Cephalalgia       Date:  2007-04       Impact factor: 6.292

4.  Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons.

Authors:  Paul L Durham; Andrew F Russo
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

Review 5.  Migraine: where and how does the pain originate?

Authors:  Karl Messlinger
Journal:  Exp Brain Res       Date:  2009-03-14       Impact factor: 1.972

Review 6.  Insights from experimental studies into allodynia and its treatment.

Authors:  Michael L Oshinsky
Journal:  Curr Pain Headache Rep       Date:  2006-06

7.  Dural administration of inflammatory soup or Complete Freund's Adjuvant induces activation and inflammatory response in the rat trigeminal ganglion.

Authors:  M Lukács; K A Haanes; Zs Majláth; J Tajti; L Vécsei; K Warfvinge; L Edvinsson
Journal:  J Headache Pain       Date:  2015-09-02       Impact factor: 7.277

8.  Acupoint injection of onabotulinumtoxin A for migraines.

Authors:  Min Hou; Jun-Fan Xie; Xiang-Pan Kong; Yi Zhang; Yu-Feng Shao; Can Wang; Wen-Ting Ren; Guang-Fu Cui; Le Xin; Yi-Ping Hou
Journal:  Toxins (Basel)       Date:  2015-10-30       Impact factor: 4.546

9.  Botulinum toxin type a therapy in migraine: preclinical and clinical trials.

Authors:  Yu-Feng Shao; Yi Zhang; Peng Zhao; Wen-Jun Yan; Xiang-Pan Kong; Lin-Lan Fan; Yi-Ping Hou
Journal:  Iran Red Crescent Med J       Date:  2013-10-05       Impact factor: 0.611

10.  Chiropractic spinal manipulative therapy for migraine: a study protocol of a single-blinded placebo-controlled randomised clinical trial.

Authors:  Aleksander Chaibi; Jūratė Šaltytė Benth; Peter J Tuchin; Michael Bjørn Russell
Journal:  BMJ Open       Date:  2015-11-19       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.